Positron emission tomography/computed tomography (PET/CT)-positive findings before autologous SCT (auto-SCT) are associated with inferior PFS and OS in patients with relapsed Hodgkin's and diffuse large B-cell lymphoma. We classified pre-transplant PET/CT performed before auto-SCT as positive or negative to evaluate the impact of pre-transplant PET/CT in mantle cell lymphoma (MCL). In 29 patients, 17 were PET/CT( À ) and 12 were PET/CT( þ ). PET/CT( þ ) patients were younger (P ¼ 0.04), had lower MCL International Prognostic Index (MIPI, P ¼ 0.04) scores, but increased bulky adenopathy 45 cm (45% vs 13%, P ¼ 0.09). With a median follow-up of 27 months (range: 5-55 months), 7 patients relapsed (4 in the PET/CT( À ) group and 3 in the PET/CT( þ ) group) with 2 deaths in the PET/CT( þ ) group without a documented relapse. The estimated 2-year PFS was 64% (95% confidence interval (CI): 0.30-0.85) vs 87% (95% CI: 0.57-0.97) in PET/CT( þ ) and PET/CT( À ) patients, respectively (P ¼ 0.054). OS was significantly decreased in PET/CT( þ ) patients (P ¼ 0.007), with 2-year estimates of 60% (95% CI: 0.23-0.84) vs 100% in PET/CT( À ) patients. A positive pre-transplant PET/CT is associated with a poor prognosis in patients with MCL. Additional factors may impact the prognostic value of PET/CT, as several PET/CT( þ ) patients remain in remission.
INTRODUCTION
Mantle cell lymphoma (MCL) represents 3-10% of all cases of nonHodgkin's lymphoma (NHL) and remains incurable with current therapy. 1 There is no currently accepted standard front-line therapy. Many regimens have excellent response rates, but all patients will ultimately relapse. While the median progression-free survival (PFS) for R-CHOP (rituximab, CY, doxorubicin, vincristine, prednisone) is 21 months, consolidation with autologous SCT (auto-SCT ) has been shown to prolong PFS with a median of 39 months, and it is often offered to fit patients in first remission. 2, 3 The Damon regimen, including induction with MTX and augmented R-CHOP, followed by chemomobilization with etoposide, cytarabine and rituximab and auto-SCT, has continued to improve clinical outcome with a 5-year PFS of 56% and additional intensive regimens such as R-HyperCVAD (rituximab, hyperfractionated CY, doxorubicin, vincristine, prednisone, MTX, cytarabine) without auto-SCT have demonstrated a median time to treatment failure of 5.9 years in patients under 65 years. 4, 5 Despite aggressive therapy and the expanded use of auto-SCT, all patients relapse. Identifying those patients likely to relapse early vs late has been challenging. A number of prognostic factors have been described, although none are widely accepted outside of the research setting and none have been routinely evaluated with respect to treatment regimen, including auto-SCT. Identification of patients likely to relapse early post transplant may lead to the development of alternative therapeutic strategies including post transplant maintenance or consolidation approaches for high-risk patients, while limiting toxicity from prolonged therapy in low-risk patients likely to experience prolonged remission durations.
The MCL International Prognostic Index (MIPI) score is predictive of OS in all patients with MCL as well as patients undergoing auto-SCT. 6, 7 While the MIPI is often challenging to calculate in a busy clinic setting, a simplified version (sMIPI) has been developed and is associated with OS in patients undergoing auto-SCT for MCL with patients designated as low, intermediate and high risk by the sMIPI having a 5-year OS of 450% in the low and intermediate groups and 38% in the high-risk group after auto-SCT. 6, 8 Additional prognostic markers in MCL include expression of Ki-67 and SOX11, presence of NOTCH1 mutations and presence of minimal residual disease (MRD). Shortened PFS has been described after auto-SCT in patients with Ki-67 staining 435% by immunohistochemistry on diagnostic samples (P ¼ 0.03). 6, 9 Similarly, SOX11 positivity has been associated with shortened OS, with a 5-year estimate of 36% vs 78% in those not expressing SOX11 (P ¼ 0.001).
10 NOTCH1 mutations have also been described as associated with an inferior median OS of 1.43 years compared with 3.86 years in NOTCH1 wild-type patients (P ¼ 0.002). 11 In a prospective study, MRD detected in peripheral blood samples by PCR assessment of IgH or BCL-1/JK copy numbers post induction was associated with a 3-year PFS of 45% compared with 82% in patients without detectable residual disease. 12 In addition to these clinical, pathological and molecular prognostic markers, PET/CT findings may also be predictive of outcomes in patients with MCL undergoing auto-SCT. PET/CT findings have been correlated with outcomes in patients with Hodgkin's lymphoma and diffuse large B-cell lymphoma undergoing auto-SCT in multiple series, with 3-to 5-year PFS ranging from 79 to 96% in PET/CT( À ) patients compared with 23-35% in patients who are PET/CT( þ ) before auto-SCT. [13] [14] [15] In MCL, one study demonstrated superior 2-year PFS of 57% for patients who achieved a PET/CT-based complete response at the end of treatment compared with 22% in patients with residual metabolic uptake by PET/CT (P ¼ 0.011). This series included PET/CT performed at the end of 53 different courses of therapy, most of which were either front-line or after first relapse. 16 In another series of MCL patients treated in the front-line with R-HyperCVAD without auto-SCT consolidation, a positive PET/CT at the conclusion of therapy was associated with a median PFS of 11.1 months, while the median PFS for patients with a negative PET/CT was not reached (P ¼ 0.0002). 17 Little is known, however, about the significance of PET/CT findings before auto-SCT in MCL. Therefore, we performed a retrospective study of patients with MCL and available pretransplant PET/CT at the Ohio State University (OSU) reviewed by a single nuclear medicine physician according to International Harmonization Criteria 18 to determine the association of PET/CT response with PFS and OS post auto-SCT.
PATIENTS AND METHODS Patients
Data were collected on specific patient and disease-related characteristics, treatment regimens and outcomes for all MCL patients undergoing auto-SCT at OSU where a PET/CT was performed prior to auto-SCT between July 2006 and March 2011. The study was approved by the OSU Institutional Review Board.
Assessment of 18-fluorodeoxyglucose PET/CT
All PET/CT scans were performed at OSU, typically after two or more induction chemotherapy cycles and were independently reviewed by one nuclear medicine physician (NCH). Evaluated PET/CT studies were performed at a median 2.3 months (range 8 days-4.8 months) before auto-SCT and before receipt of any chemotherapy associated with stem cell mobilization or any conditioning regimen. Studies were evaluated using International Harmonization Criteria 18 with mediastinal blood pool and average liver blood pool as referenced background activity. BM uptake was not utilized in the PET/CT response determination.
Assessment of response by CT
In addition to evaluation of PET/CT before transplantation, we also evaluated the responses by CT criteria 19 for all patients with available CT scan reports before and after induction therapy. Post-induction CT was performed at a median of 2.3 months before transplant (range: 1.4-2.8 months). Response assessment was performed using 2007 International Response Criteria 19 incorporating CT and BM biopsy findings. CT-based responses were correlated with PET/CT findings and discordant cases are described herein.
Statistical analysis
Associations between PET/CT positivity and clinical characteristics were performed using Fisher's exact test for categorical variables or Wilcoxon's rank-sum test for continuous variables. PFS was calculated from the date of transplant to the date of relapse or death from any cause, censoring patients who were progression-free and alive at last follow-up. Relapse/ progression was defined as a new biopsy confirming recurrent MCL, new or progressive lesions on imaging studies or initiation of new therapy for MCL. OS was calculated from the date of transplant to the date of death or last follow-up. Estimates of PFS and OS were obtained using the KaplanMeier method and differences in survival distributions between PET/CT( þ ) and PET/CT( À ) groups were tested using the log-rank test. Univariable proportional hazards models for PFS were fit to obtain hazard ratio estimates and 95% confidence intervals (CIs). All tests were two-sided and statistical significance was declared at a ¼ 0.05. Meaningful multivariable modeling to adjust for potential confounding covariates was limited because of the small number of events in this cohort of patients.
RESULTS

Patient and disease characteristics
In all, 29 patients with MCL who underwent auto-SCT at OSU from July 2006 to March 2011 had available pre-transplant PET/CT, including 26 patients undergoing auto-SCT in first remission and three patients who underwent auto-SCT in subsequent remissions after 2, 3 or 5 prior regimens. Median time from diagnosis to transplant was 5.4 months (range 3.4-82 months), and median time from the date of the last pre-transplant cycle to the date of the pre-transplant PET/CT was 17 days (range: 6-103 days). In total, 17 patients were PET/CT( À ) and 12 patients were PET/ CT( þ ) using International Harmonization Criteria, 18 with 100% concordance utilizing mediastinal blood pool vs average liver activity as referenced background. Baseline demographic and diagnostic characteristics for all patients and by PET/CT status are shown in Table 1 . In all 29 patients, the median age was 60 years (range: 37-73 years) and the majority (86%) of patients were male. All patients had stage IV disease, including 93% of patients with BM involvement and 7% of patients with multiple extranodal sites, including the central nervous system, gastrointestinal tract, pancreas and tongue. Patients who were PET/CT( þ ) were younger, with a median age of 55 compared with 62 in patients who were PET/CT( À ) (P ¼ 0.04). Among the 25 patients with available MIPI and sMIPI calculations, the median scores were 5.9 (range: 4.9-7.0) and 8 (range: 0-9), respectively. Higher scores were more frequent in PET/CT( À ) patients, where 40% had high-risk scores of at least 6.2, as opposed to the PET/CT( þ ) patients, where no one had a high-risk MIPI score (Table 1) . Of 29 patients, 26 had pre-treatment imaging available to evaluate for bulky adenopathy, and 27% of patients had adenopathy 45 cm, while 12% of patients had nodes 410 cm. Bulky disease 45 cm occurred in 45% of PET/CT( þ ) patients and only 13% of PET/CT( À ) patients (P ¼ 0.09). Further, all three patients with bulky adenopathy 410 cm were PET/CT( þ ). No significant differences in gender, Eastern Cooperative Oncology Group performance status and pre-treatment lactate dehydrogenase or WBC count were noted between the PET/CT( þ ) and PET/ CT( À ) patients.
Therapy received 66% of patients received two cycles of induction therapy, 21% received 3-5 cycles and 14% received X6 cycles prior to any chemo-mobilization or conditioning regimens. Most patients (62%) received the Damon regimen, including induction with MTX with augmented R-CHOP and etoposide, cytarabine and rituximab mobilization. Conditioning regimens included BEAM (BCNU, etoposide, cytarabine, melphalan) in 59% of patients and BEC (BCNU, etoposide, CY) in 41% of patients. The median number of infused CD34 þ cells was 6.89 Â 10 6 (range: 1.78-40.41). There were no significant differences between PET/CT( þ ) and PET/CT( À ) patients with regards to these treatment-related variables, although the number of infused CD34 þ cells tended to be higher in PET/CT( þ ) patients with a median of 10.53 Â 10 6 vs 5.26 Â 10 6 in the PET/ CT( À ) patients (P ¼ 0.08). Post-transplant maintenance or consolidation therapy with bortezomib or vorinostat was administered in 45% of patients, including 42% of PET/CT( þ ) patients and 47% of PET/CT( À ) patients (P ¼ 1.00).
Post-transplant outcomes With a median follow-up of 27 months (range: 5-55 months), 7 patients have relapsed, including 4 of 17 PET/CT( À ) and 3 of 12 PET/CT( þ ) patients. In addition, there have been two deaths from pneumonia without evidence of disease progression, at 5 and 33 months post transplant, both in PET/CT( þ ) patients. Among all 29 patients, the estimated 2-year PFS was 78% (95% CI: 0.57-0.89). Although not statistically significant, PFS was shorter in PET/CT( þ ) patients compared with PET/CT( À ) patients (Figure 1a ; P ¼ 0.054), In addition to the two pneumonia-related deaths, there have been four deaths due to disease, including three PET/CT( þ ) patients and one PET/CT( À ) patient. The 2-year OS estimate for the entire cohort was 84% (95% CI: 0.62-0.94). OS was significantly shorter in the PET/CT( þ ) patients compared with PET/CT( À ) patients (Figure 1b ; P ¼ 0.007). At 2 years, the OS estimate among PET/CT( þ ) patients was 60% (95% CI: 0.23-0.84), whereas no one with a negative PET/CT had expired. The only clinical variable that was strongly associated with PFS was the presence of bulky adenopathy 45 cm (Figures 2a; P ¼ 0.01) . The remaining clinical variables assessed by univariable analysis for an association with PFS are described in Table 2 , and none were significantly associated with PFS. Since bulky disease was also more often present in PET/CT( þ ) patients, we explored the subsets of patients with and without bulky disease in relation to PFS, according to PET/CT status (Figure 2b ). In the five patients who had bulky disease and were PET/CT( þ ), two progressed, one died from pneumonia and two remain in remission at 12-13 months post transplant. Only two patients had bulky disease and were PET/CT( À ); one remains in remission at 20 months, while the other had a late relapse at 42 months. Among the six patients without bulky disease who were PET/CT( þ ), five remain disease free from 17-39 months post transplant, while one died of pneumonia without relapse 33 months after auto-SCT (Figure 2b months post transplant (median: 33 months). Hence, it appears as if PET/CT( þ ) patients who also have bulky adenopathy may experience events more quickly, whereas those with PET/CT( þ ) and without bulky adenopathy may behave more similarly to those who were PET/CT( À ) before transplant. In total, 15 patients had a PET/CT performed after their SCT that was available for review, including 4 positive scans and 11 negative scans. One patient had a positive pre-transplant PET/CT that was negative after transplant, and he subsequently has relapsed and died from his disease. The results for the 14 remaining available post-treatment scans did not change between the pre-and post transplant scans.
Analysis of response and outcomes by CT criteria In all, 16 patients were evaluable for response by CT based on comparisons of pre-induction and pre-transplant CT imaging. The 13 remaining patients could not be assessed for CT-based response due to lack of measurable disease 41cm (n ¼ 4) or absence of either pre-treatment or pre-transplant CT scans (n ¼ 9). Of the 16, nine achieved CR, one achieved PR and six had stable disease. CT results were clearly concordant with PET/CT in 11 patients (69%) (that is, seven with CR by CT and PET/CT( À ) and with stable disease by CT and PET/CT( þ )). Patient outcomes for the five discordant results are described in Table 3 .
DISCUSSION
MCL remains a challenging disease to evaluate and manage due to the lack of satisfactory curative therapy and the heterogeneous disease course. Many patients are likely to experience prolonged remission durations even without aggressive upfront therapy or consolidation with auto-SCT in first remission, whereas others rapidly progress despite auto-SCT or aggressive combination chemotherapy. Effective, feasible prognostic markers are needed to identify which patients are at the highest risk for rapid disease progression that may benefit from novel therapies or maintenance strategies. Previously described markers, including Ki-67 proliferative index and MRD correlate with PFS after transplant. However, it remains unclear whether Ki-67 should be interpreted as a continuous variable as it is with the biologic MIPI or with set cutpoints (that is, 435%). 6, 9, 18 In addition, there remains no standard method to determine MRD.
Several series have demonstrated an advantage in PFS and OS for patients with relapsed/refractory DLCL or Hodgkin's lymphoma with a negative PET/CT before auto-SCT. [13] [14] [15] In MCL, endof-treatment PET/CT is prognostic for PFS in non-transplant patients, both in a heterogeneously treated population and a population uniformly treated with R-HyperCVAD in the front-line setting. 16, 17 The role of PET/CT continues to expand in the management of NHL, and despite prior uncertainty regarding its utility in indolent NHL, patients completing induction with chemoimmunotherapy and embarking on a maintenance regimen of rituximab who have a positive PET/CT appear to have inferior PFS at 42 months (32.9%) compared with PET/CT( À )patients (70.7%, Po0.001). 20 We present one of the first series to date evaluating the role of pre-transplant PET/CT in MCL.
In this study, we demonstrated that OS was significantly shorter in patients who are PET/CT( þ ) before auto-SCT compared with patients who are PET/CT( À ) (P ¼ 0.007), where 2-year OS estimates were 60% and 100%, respectively. Differences in PFS approached statistical significance, favoring the PET/CT( À ) group with 2-year PFS estimates of 87% compared with 64% in those patients who were PET/CT( þ ). In addition to PET/CT results, the presence of bulky adenopathy was also associated with inferior PFS as all but one of the events in the PET/CT( þ ) group have involved patients with bulky adenopathy (Figure 2b) . CT-assessed response appeared to generally associate with PET/CT response, although 5 of 16 evaluable patients had discordant results, including two patients with stable disease by the CT criteria, but who had a negative PET/CT and subsequently experienced prolonged remissions (Table 3) . Therefore, this limited series suggests a role for PET/CT before auto-SCT in patients with MCL. However, as only 3 of 12 PET/CT( þ ) patients in our series have relapsed after a median of 27 months of follow-up, we would not yet advocate the use of PET/CT to disqualify patients for auto-SCT in the absence of other clinical signs of progression. Rather, a positive PET/CT may be useful when risk stratifying patients, especially in the setting where alternative therapies including post transplant maintenance may be available in the setting of a clinical trial.
Our 2-year PFS estimates of 64% in the PET/CT( þ ) and 87% in PET/CT( À ) patients are comparable to the estimated 1.5-year PFS post-transplant of 57% for intermediate-risk MIPI and 87% for patients with low-risk MIPI described in a recent series. 7 However, as the PET/CT( À ) patients had an increased median MIPI score compared with the PET/CT( þ ) patients, with all of the highrisk MIPI scores classified as PET/CT( À ), it is challenging to make a meaningful comparison based on this current series, except to suggest that low-risk patients by MIPI who fail to achieve a CR by PET/CT may remain at increased risk for early relapse despite a low MIPI. However, additional inferences regarding the representative contributions of MIPI and pre-transplant PET/CT to patient outcome would be premature given the retrospective nature of this limited series, and it remains unclear why the median MIPI was increased in the PET/CT( À ) patients. Larger series will be needed to further illuminate any potential association between MIPI and pretransplantation PET/CT.
In conclusion, our data indicate that pre-transplant PET/CT is significantly associated with inferior OS and may also predict shortened PFS in patients with MCL undergoing auto-SCT. Additional prospective studies are required to confirm this observation in a larger patient sample and to determine the significance of PET/CT with respect to other known prognostic markers including the MIPI, sMIPI and Ki-67 expression in patients with MCL undergoing auto-SCT. Although PET/CT is employed ubiquitously, centralized review by nuclear medicine physicians experienced in evaluation of lymphoma is essential in future studies aimed at evaluating the role of PET/CT in management of MCL. While the International Harmonization criteria are employed frequently, additional criteria, including those described by Meignan et al, 21 must also be considered in future studies and may improve the predictive accuracy of PET/CT in patients with MCL after initial chemotherapy and before auto-SCT. Ultimately such studies may guide therapeutic decisions in MCL, with the use of a combination of prognostic markers, potentially including PET/CT, to identify high-risk patients and development of alternative therapies or maintenance strategies for these patients that may lead to improved long-term outcomes in MCL.
